Projects

RNDr. Dana Jurkovičová, DrSc.
scientific researcher

International

Current
  • Precision medicine in biliary tract cancer
    Program: COST
    Duration: 9. 10. 2023 – 8. 10. 2027
  • Translational control in Cancer European Network
    Program: COST
    Duration: 4. 10. 2022 – 3. 10. 2026
Finished
  • New diagnostic and therapeutic tools against multidrug resistant tumors
    Program: COST
    Duration: 11. 9. 2018 – 10. 9. 2022
  • INNOVATIVE PARTNERSHIP FOR ACTION AGAINST CANCER
    Program: Other
    Duration: 1. 4. 2018 – 31. 12. 2021

National

Current
  • Role of DNA damage and repair in response of urogenital cancers to cisplatin-based chemotherapy
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2026
  • Nanoceria - the complementary treatment to sensitize testicular tumors not responding to platinum agents
    Program: VEGA
    Duration: 1. 1. 2025 – 31. 12. 2025
  • The emerging role of the microbiome in hematologic cancer patients receiving high-dose chemotherapy with hematopoietic stem cell transplantation.
    Program: VEGA
    Duration: 1. 1. 2022 – 31. 12. 2025
Finished
  • Is hypoxia a master modulator of DNA repair capacity and mitochondrial dynamics in chemotherapy response in urogenital malignancies?
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Is HIF-1a a master regulator of DNA repiar capacity and chemotherapy response in testicular germ cell tumors?
    Program: SRDA
    Duration: 1. 7. 2020 – 31. 12. 2023
  • Identification of biomarkers of resistance to cisplatin-based chemotherapy in urogenital cancer
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • Markers overlapping chemoresistance and metastatic potential in colorectal cancer - aldehyde dehydrogenase and its clinical relevance
    Program: Other projects
    Duration: 1. 11. 2019 – 31. 12. 2022
  • Regulation of epithelial-mesenchymal transition by microRNA and promoter methylation in invasive breast cancer
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • Molecular biomarkers of relapse in seminoma clinical stage I patients
    Program: Other projects
    Duration: 1. 10. 2019 – 21. 12. 2022
  • Turning cisplatin-resistant testiular germ cell tumors into a curable disease
    Program: SRDA
    Duration: 1. 8. 2018 – 31. 12. 2021
  • Is DNA repair beyond good curability in testicular germ cell tumours?
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
Employees